Health care stocks were mixed premarket Wednesday as the iShares Biotechnology ETF (IBB) was 0.2% lower and the Health Care Select Sector SPDR Fund (XLV) was up 0.1% recently.
Sagimet Biosciences (SGMT) shares were rising by more than 14% after the company said denifanstat met primary and secondary endpoints in a phase 3 clinical trial to treat moderate to severe acne vulgaris.
Merus (MRUS) shares were down more than 7% after the company priced an underwritten public offering of about 5.3 million common shares at $57 per share for expected gross proceeds of about $300 million.
AnaptysBio (ANAB) shares were up more than 3% after the company reported updated interim results from its ongoing phase 2b trial of rosnilimab in patients with moderate-to-severe rheumatoid arthritis, showing that most participants improved after three months of treatment, with many maintaining those gains for at least two months after stopping therapy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.